Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis - 03/06/16
, Julia Deinzer, MD a, Anne-Kathrin Fiege, MD a, Valerie von Gruben, MD a, Anna-Lena Sack, MD a, Alice Thraen, MD a, Peter Weisenseel, MD a, Kristine Breuer, MD, PhD a, Stefan Jäckle, MD, PhD c, Markus Meier, MD, PhD b, c, d| Miltenyi Biotech provided an unrestricted grant used to support data collection and analysis, as well as medical writing. |
|
| Disclosure of potential conflict of interest: K. Reich serves on the board, receives research funding, and receives payments for lectures and educational development from AbbVie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Takeda, UCB Pharma, and Xenoport. A.-K. Fiege receives fees from Nephrologisches Zentrum for participation in review activities. P. Weisenseel receives honoraria for participation in clinical studies in atopic dermatitis novel mAbs. K. Breuer receives payments form lectures from ALK-Abelló, Novartis, HAL Allergy, Stallergenes, and GlaxoSmithKline and has received travel support form Novartis and Stallergenes. M. Meier receives research funding from the Interdisciplinary Apheresis Center. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 6
P. 1882 - juin 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
